A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies

Clinical trial NCT02118337 · COMPLETED

Trial details

NCT number: NCT02118337
Sponsor: MedImmune LLC
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Select Advanced Malignancies Kidney Cancer Clear Cell Renal Cell Carcinoma

Start date: 2014-05-19
Primary completion: 2020-03-17
Enrollment: 97

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.